{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:47:55Z","timestamp":1785041275256,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00223-018-0406-4","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T05:29:05Z","timestamp":1518845345000},"page":"206-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacological Inhibition of the Skeletal IKK\u03b2 Reduces Breast Cancer-Induced Osteolysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Silvia","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan T.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mollat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen I.","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"406_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm1519","volume":"13","author":"BK Park","year":"2007","unstructured":"Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13:62\u201369","journal-title":"Nat Med"},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"5656","DOI":"10.1158\/1078-0432.CCR-08-0123","volume":"14","author":"DF Lee","year":"2008","unstructured":"Lee DF, Hung MC (2008) Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 14:5656\u20135662","journal-title":"Clin Cancer Res"},{"key":"406_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/cr.2008.273","volume":"18","author":"JF Clement","year":"2008","unstructured":"Clement JF, Meloche S, Servant MJ (2008) The IKK-related kinases: from innate immunity to oncogenesis. Cell Res 18:889\u2013899","journal-title":"Cell Res"},{"key":"406_CR4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1242\/jcs.115.1.141","volume":"115","author":"AV Gasparian","year":"2002","unstructured":"Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115:141\u2013151","journal-title":"J Cell Sci"},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/j.1365-2141.2007.06629.x","volume":"138","author":"M Jourdan","year":"2007","unstructured":"Jourdan M, Moreaux J, Vos JD, Hose D, Mahtouk K, Abouladze M, Robert N, Baudard M, Reme T, Romanelli A, Goldschmidt H, Rossi JF, Dreano M, Klein B (2007) Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 138:160\u2013168","journal-title":"Br J Haematol"},{"key":"406_CR6","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nature05656","volume":"446","author":"JL Luo","year":"2007","unstructured":"Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690\u2013694","journal-title":"Nature"},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/1078-0432.CCR-06-1559","volume":"13","author":"Y Kishida","year":"2007","unstructured":"Kishida Y, Yoshikawa H, Myoui A (2007) Parthenolide, a natural inhibitor of Nuclear Factor-kappaB, inhibits lung colonization of murine osteosarcoma cells. Clin Cancer Res 13:59\u201367","journal-title":"Clin Cancer Res"},{"key":"406_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/187569211796957584","volume":"9","author":"A Crawford","year":"2011","unstructured":"Crawford A, Nahta R (2011) Targeting Bcl-2 in herceptin-resistant breast cancer cell lines. Curr Pharmacogenom Personal Med 9:184\u2013190","journal-title":"Curr Pharmacogenom Personal Med"},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"e18447","DOI":"10.1371\/journal.pone.0018447","volume":"6","author":"L Wu","year":"2011","unstructured":"Wu L, Shao L, An N, Wang J, Pazhanisamy S, Feng W, Hauer-Jensen M, Miyamoto S, Zhou D (2011) IKKbeta regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS ONE 6:e18447","journal-title":"PLoS ONE"},{"key":"406_CR10","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.cellsig.2012.01.012","volume":"24","author":"T Tezil","year":"2012","unstructured":"Tezil T, Bodur C, Kutuk O, Basaga H (2012) IKK-beta mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death. Cell Signal 24:1361\u20131368","journal-title":"Cell Signal"},{"key":"406_CR11","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.1038\/srep04057","volume":"4","author":"K Oida","year":"2014","unstructured":"Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E, Matsuda H, Tanaka A (2014) Nuclear factor-kB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep 4:4057","journal-title":"Sci Rep"},{"key":"406_CR12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","volume":"328","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679\u2013687","journal-title":"Biochem Biophys Res Commun"},{"key":"406_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2013.07.036","volume":"154","author":"XH Zhang","year":"2013","unstructured":"Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens JA, Massague J (2013) Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154:1060\u20131073","journal-title":"Cell"},{"key":"406_CR14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/cr.2008.30","volume":"18","author":"M Karin","year":"2008","unstructured":"Karin M (2008) The IkappaB kinase\u2014a bridge between inflammation and cancer. Cell Res 18:334\u2013342","journal-title":"Cell Res"},{"key":"406_CR15","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/emboj\/20.6.1271","volume":"20","author":"N Kobayashi","year":"2001","unstructured":"Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271\u20131280","journal-title":"EMBO J"},{"key":"406_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1101\/gad.13.8.1015","volume":"13","author":"MA Lomaga","year":"1999","unstructured":"Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der HA, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13:1015\u20131024","journal-title":"Genes Dev"},{"key":"406_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2443.1999.00265.x","volume":"4","author":"A Naito","year":"1999","unstructured":"Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4:353\u2013362","journal-title":"Genes Cells"},{"key":"406_CR18","doi-asserted-by":"publisher","first-page":"54841","DOI":"10.1074\/jbc.M406392200","volume":"279","author":"ML Chaisson","year":"2004","unstructured":"Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC (2004) Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha. J Biol Chem 279:54841\u201354848","journal-title":"J Biol Chem"},{"key":"406_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1084\/jem.20042081","volume":"201","author":"MG Ruocco","year":"2005","unstructured":"Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu LC, Cao Y, Schett G, Wagner EF, Karin M (2005) I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677\u20131687","journal-title":"J Exp Med"},{"key":"406_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/en.2008-0998","volume":"150","author":"AI Idris","year":"2009","unstructured":"Idris AI, Greig IR, Bassonga-Landao E, Ralston SH, t Hof RJ (2009) Identification of Novel biphenyl carboxylic acid derivatives as novel antiresorptive agents that do not impair parathyroid hormone-induced bone formation. Endocrinology 150:5\u201313","journal-title":"Endocrinology"},{"key":"406_CR21","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1158\/1535-7163.MCT-09-0133","volume":"8","author":"AI Idris","year":"2009","unstructured":"Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH (2009) Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther 8:2339\u20132347","journal-title":"Mol Cancer Ther"},{"key":"406_CR22","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1096\/fj.10-164095","volume":"24","author":"AI Idris","year":"2010","unstructured":"Idris AI, Krishnan M, Simic P, Landao-Bassonga E, Mollat P, Vukicevic S, Ralston SH (2010) Small molecule inhibitors of I{kappa}B kinase signaling inhibit osteoclast formation in vitro and prevent ovariectomy-induced bone loss in vivo. FASEB J 24:4545\u20134555","journal-title":"FASEB J"},{"key":"406_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00223-010-9417-5","volume":"87","author":"AI Idris","year":"2010","unstructured":"Idris AI, Coste E, Greig IR, Ralston SH, van\u2019t Hof RJ (2010) The biphenyl-carboxylate derivative ABD328 is a novel orally active antiresorptive agent. Calcif Tissue Int 87:525\u2013532","journal-title":"Calcif Tissue Int"},{"key":"406_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jbmr.4","volume":"25","author":"JE Otero","year":"2010","unstructured":"Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y (2010) IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res 25:1282\u20131294","journal-title":"J Bone Miner Res"},{"key":"406_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm.1954","volume":"15","author":"J Chang","year":"2009","unstructured":"Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY (2009) Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat Med 15:682\u2013689","journal-title":"Nat Med"},{"key":"406_CR26","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1210\/en.2010-0399","volume":"151","author":"N Alles","year":"2010","unstructured":"Alles N, Soysa NS, Hayashi J, Khan M, Shimoda A, Shimokawa H, Ritzeler O, Akiyoshi K, Aoki K, Ohya K (2010) Suppression of NF-kappaB increases bone formation and ameliorates osteopenia in ovariectomized mice. Endocrinology 151:4626\u20134634","journal-title":"Endocrinology"},{"key":"406_CR27","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.canlet.2017.09.034","volume":"410","author":"S Marino","year":"2017","unstructured":"Marino S, Bishop RT, Logan JG, Mollat P, Idris AI (2017) Pharmacological evidence for the bone-autonomous contribution of the NFkappaB\/beta-catenin axis to breast cancer related osteolysis. Cancer Lett 410:180\u2013190","journal-title":"Cancer Lett"},{"key":"406_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bbrc.2004.08.083","volume":"323","author":"J Kamon","year":"2004","unstructured":"Kamon J, Yamauchi T, Muto S, Takekawa S, Ito Y, Hada Y, Ogawa W, Itai A, Kasuga M, Tobe K, Kadowaki T (2004) A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem Biophys Res Commun 323:242\u2013248","journal-title":"Biochem Biophys Res Commun"},{"key":"406_CR29","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","volume":"105","author":"A Tanaka","year":"2005","unstructured":"Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, Itai A, Matsuda H (2005) A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105:2324\u20132331","journal-title":"Blood"},{"key":"406_CR30","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1074\/jbc.M209677200","volume":"278","author":"JR Burke","year":"2003","unstructured":"Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, Yang X, Iotzova VS, Clarke W, Strnad J, Qiu Y, Zusi FC (2003) BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278:1450\u20131456","journal-title":"J Biol Chem"},{"key":"406_CR31","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1002\/jbmr.1951","volume":"28","author":"N Rucci","year":"2013","unstructured":"Rucci N, Capulli M, Ventura L, Angelucci A, Peruzzi B, Tillgren V, Muraca M, Heinegard D, Teti A (2013) Proline\/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss. J Bone Miner Res 28:1912\u20131924","journal-title":"J Bone Miner Res"},{"key":"406_CR32","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/jbmr.1847","volume":"28","author":"JG Logan","year":"2013","unstructured":"Logan JG, Sophocleous A, Marino S, Muir M, Brunton VG, Idris AI (2013) Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis. J Bone Miner Res 28:1229\u20131242","journal-title":"J Bone Miner Res"},{"key":"406_CR33","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1210\/endo-125-3-1142","volume":"125","author":"BF Boyce","year":"1989","unstructured":"Boyce BF, Aufdemorte TB, Garrett IR, Yates AJP, Mundy GR (1989) Effects of interleukin-1 on bone turnover in normal mice. Endocrinology 125:1142\u20131150","journal-title":"Endocrinology"},{"key":"406_CR34","first-page":"564","volume":"3","author":"GM Campbell","year":"2014","unstructured":"Campbell GM, Sophocleous A (2014) Quantitative analysis of bone and soft tissue by micro-computed tomography: applications to ex vivo and in vivo studies. Bone Key Rep 3:564","journal-title":"Bone Key Rep"},{"key":"406_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2\u201317","journal-title":"J Bone Miner Res"},{"key":"406_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bonekey.2014.80","volume":"3","author":"SE Taylor","year":"2014","unstructured":"Taylor SE, Shah M, Orriss IR (2014) Generation of rodent and human osteoblasts. BoneKEy Rep 3:585","journal-title":"BoneKEy Rep"},{"key":"406_CR37","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0022-1759(97)00043-4","volume":"204","author":"GR Nakayama","year":"1997","unstructured":"Nakayama GR, Caton MC, Nova MP, Parandoosh Z (1997) Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods 204:205\u2013208","journal-title":"J Immunol Methods"},{"key":"406_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-1-61779-415-5_3","volume":"816","author":"IR Orriss","year":"2012","unstructured":"Orriss IR, Taylor SE, Arnett TR (2012) Rat osteoblast cultures. Methods Mol Biol 816:31\u201341","journal-title":"Methods Mol Biol"},{"key":"406_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1385\/1-59259-366-6:145","volume-title":"Bone research protocols","author":"RJ Hof van\u2019t","year":"2003","unstructured":"van\u2019t Hof RJ (2003) Osteoclast formation in the mouse coculture assay. In: Helfrich MH, Ralston SH (eds) Bone research protocols. Humana Press, Totowa, pp\u00a0145\u2013152"},{"key":"406_CR40","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/rheumatology\/39.9.1004","volume":"39","author":"RJ Hof van\u2019t","year":"2000","unstructured":"van\u2019t Hof RJ, Hocking L, Wright PK, Ralston SH (2000) Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology (Oxford) 39:1004\u20131008","journal-title":"Rheumatology (Oxford)"},{"key":"406_CR41","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1210\/edrv.20.3.0367","volume":"20","author":"T Suda","year":"1999","unstructured":"Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345\u2013357","journal-title":"Endocr Rev"},{"key":"406_CR42","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655\u20131664","journal-title":"N Engl J Med"},{"key":"406_CR43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10555-006-9023-1","volume":"25","author":"VA Siclari","year":"2006","unstructured":"Siclari VA, Guise TA, Chirgwin JM (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastas Rev 25:621\u2013633","journal-title":"Cancer Metastas Rev"},{"key":"406_CR44","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593","journal-title":"Nat Rev Cancer"},{"key":"406_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"406_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5483\/BMBRep.2014.47.8.206","volume":"47","author":"JY Kim","year":"2014","unstructured":"Kim JY, Cheon YH, Yoon KH, Lee MS, Oh J (2014) Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis. BMB Rep 47:451\u2013456","journal-title":"BMB Rep"},{"key":"406_CR47","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","volume":"140","author":"RJ Thomas","year":"1999","unstructured":"Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ, Martin TJ, Gillespie MT (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451\u20134458","journal-title":"Endocrinology"},{"key":"406_CR48","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18:1378\u20131391","journal-title":"J Clin Oncol"},{"key":"406_CR49","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","volume":"91","author":"JR Berenson","year":"2001","unstructured":"Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191\u20131200","journal-title":"Cancer"},{"key":"406_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD, Myeloma Aredia Study Group (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488\u2013493","journal-title":"N Engl J Med"},{"key":"406_CR51","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK (2011) Cancer to bone: a fatal attraction. Nat Rev Cancer 11:411\u2013425","journal-title":"Nat Rev Cancer"},{"key":"406_CR52","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"406_CR53","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1359\/jbmr.090810","volume":"25","author":"JJ Body","year":"2010","unstructured":"Body JJ, Lipton A, Gralow J, Steger GG, Gao G, Yeh H, Fizazi K (2010) Effects of denosumab in patients with bone metastases, with and without previous bisphosphonate exposure. J Bone Miner Res 25:440\u2013446","journal-title":"J Bone Miner Res"},{"key":"406_CR54","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/nm.4118","volume":"22","author":"E Nolan","year":"2016","unstructured":"Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ (2016) RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 22:933\u2013939","journal-title":"Nat Med"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-018-0406-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-018-0406-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T13:31:50Z","timestamp":1660483910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-018-0406-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1007\/s00223-018-0406-4","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Patrick Mollat is an employee of Galapagos SASU (102 Avenue Gaston Roussel, 93230 Romainville, France). Silvia Marino, Ryan T. Bishop and Aymen I. Idris declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures involving mice and their care were approved by and performed in compliance with the guidelines of Institutional Animal Care and Use Committee of University of Edinburgh (Scotland, UK).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}